Esperion Therapeutics Inc. [NASDAQ: ESPR] price surged by 9.42 percent to reach at $0.18. The one-year ESPR stock forecast points to a potential upside of 71.79. The average equity rating for ESPR stock is currently 1.75, trading closer to a bullish pattern in the stock
Esperion Therapeutics Inc. [NASDAQ: ESPR] traded at a low on Monday, posting a -9.58 loss after which it closed the day’ session at $1.93. The results of the trading session contributed to over 6809030 shares changing hands. Over the past one week, the price volatility
Esperion Therapeutics Inc. [NASDAQ: ESPR] price surged by 4.18 percent to reach at $0.13. The company report on April 7, 2024 at 2:45 PM that Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations
Esperion Therapeutics Inc. [NASDAQ: ESPR] surged by $0.11 during the normal trading session on while it closed the day at $2.79. The company report on April 1, 2024 at 8:00 AM that Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024. “We are honored
Esperion Therapeutics Inc. [NASDAQ: ESPR] stock went on an upward path that rose over 14.41% on Monday, amounting to a one-week price increase of more than 27.80%. The company report on March 25, 2024 at 4:00 PM that Esperion Announces Data from CLEAR Outcomes Sub-Groups
Esperion Therapeutics Inc. [NASDAQ: ESPR] loss -3.65% on the last trading session, reaching $2.11 price per share at the time. The company report on February 27, 2024 at 6:00 AM that Esperion Reports Fourth Quarter and Full Year 2023 Financial Results. – FY23 U.S. Net
Esperion Therapeutics Inc. [NASDAQ: ESPR] loss -6.39% or -0.14 points to close at $2.05 with a heavy trading volume of 5603080 shares. The company report on February 27, 2024 at 6:00 AM that Esperion Reports Fourth Quarter and Full Year 2023 Financial Results. – FY23
Esperion Therapeutics Inc. [NASDAQ: ESPR] loss -7.32% on the last trading session, reaching $2.28 price per share at the time. The company report on February 27, 2024 at 6:00 AM that Esperion Reports Fourth Quarter and Full Year 2023 Financial Results. – FY23 U.S. Net
Esperion Therapeutics Inc. [NASDAQ: ESPR] closed the trading session at $2.90. The company report on February 27, 2024 at 6:00 AM that Esperion Reports Fourth Quarter and Full Year 2023 Financial Results. – FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23
Esperion Therapeutics Inc. [NASDAQ: ESPR] loss -2.61% on the last trading session, reaching $2.61 price per share at the time. The company report on February 16, 2024 at 4:30 PM that Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4). The 2017 Inducement Equity Incentive
© 2024, Powered by Smart TechOne
